Table 2.

Patient-level association for time-to-event outcomesa

iGFR-Based OutcomeeGFR-Based Outcome
Halving of eGFR or ESRD EventNo EventTotal
Halving of iGFR or ESRD event223 (20.4%)57 (5.2%)280 (25.6%)
No event17 (1.6%)797 (72.9%)814 (74.4%)
Total240 (21.9%)854 (78.1%)1094 (100%)
  • a Shown is the relationship between the numbers (overall percentages) of patients who reached the composite end points of halving of estimated GFR (eGFR) or ESRD or of having of iothalamate GFR (iGFR) or ESRD during the follow-up period of the African American Study of Kidney Disease and Hypertension (AASK). The κ statistic relating the composite outcomes was 0.81.